Geode Capital Management LLC increased its stake in SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) by 10.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 398,856 shares of the company’s stock after buying an additional 36,405 shares during the period. Geode Capital Management LLC’s holdings in SCYNEXIS were worth $594,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, XTX Topco Ltd purchased a new stake in shares of SCYNEXIS in the 3rd quarter worth approximately $25,000. Institutional investors own 54.37% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded SCYNEXIS from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.
SCYNEXIS Stock Performance
Shares of SCYX opened at $1.23 on Friday. The business’s fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $1.53. SCYNEXIS, Inc. has a 12 month low of $0.90 and a 12 month high of $3.07. The company has a market cap of $46.68 million, a price-to-earnings ratio of -1.66 and a beta of 1.53.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The business had revenue of $0.66 million for the quarter. As a group, research analysts forecast that SCYNEXIS, Inc. will post -0.55 EPS for the current year.
SCYNEXIS Company Profile
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Further Reading
- Five stocks we like better than SCYNEXIS
- Differences Between Momentum Investing and Long Term Investing
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Investing in the High PE Growth Stocks
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Want to see what other hedge funds are holding SCYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report).
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
